ArticleScientific reports2025
Machine learning analysis of coagulation-related genes for breast cancer diagnosis and prognosis prediction.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Machine learning-based programmed cell death gene signature for prognosis and drug sensitivity in breast cancer.Oncology letters · 2026Article
- Lymphangiogenesis-related gene signature-based risk model for prognostic assessment of cervical cancer: immune-metabolic characterization and molecular subtype analysis.Frontiers in genetics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The purpose of this study was to investigate the relationship between coagulation related genes (CRGs) and breast cancer (BC). First, we found that most CRGs are abnormally expressed in BC patients and correlated with their prognosis. Therefore, we explored the expression of CRGs in benign and malignant breast tissues in the Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx), extracted differentially expressed CRGs, and established an artificial neural network (ANN) diagnostic model to distinguish the nature of breast tissues, as well as a risk scoring model for prognostic assessment and risk stratification. The specimen transcriptomic data we provided confirmed the diagnostic performance of the ANN model described above. For the risk score model, we used internal and external validation, using ROC curves and C-index values to test its predictive value in the TCGA and Gene Expression Omnibus (GEO) cohorts, and further established a prognostic nomogram for clinical application. In addition, we evaluated the performance of diagnostic and prognostic models using 3 cross-validations methods. RABIF was further identified as a core gene. We performed a more detailed study of RABIF: RT-qPCR of BC cell lines and immunohistochemical staining (IHC) of breast tissue samples showed that RABIF is highly expressed in BC especially in advanced BC. Our study demonstrates the value of CRGs as diagnostic and prognostic targets and may contribute to clinical decision-making in BC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.